Initial Characterization and Toxicology of an Nmt Inhibitor in Development for Hematologic Malignancies

肉豆蔻酰化 达沙替尼 激酶 林恩 癌症研究 原癌基因酪氨酸蛋白激酶Src 伊布替尼 细胞凋亡 化学 生物 细胞生长 白血病 药理学 慢性淋巴细胞白血病 髓系白血病 生物化学 免疫学 磷酸化 伊马替尼
作者
Michael J. Weickert,John E. Dillberger,John Robert Mackey,Paul Graham Wyatt,David W. Gray,Kevin D. Read,Christian Li,Audrey Parenteau,Luc G. Berthiaume
出处
期刊:Blood [Elsevier BV]
卷期号:134 (Supplement_1): 3362-3362 被引量:7
标识
DOI:10.1182/blood-2019-124934
摘要

N-myristoylation, the addition of the 14-carbon fatty acid to proteins, plays a fundamental role in cell signaling. Over 200 proteins are myristoylated, including the Src Family Kinases (SFK) Src, Lyn, Lck, Hck, and Fgr, as well as c-Abl, Gα subunits, caspase truncated (ct-) Bid and ct-PAK2, regulating cell growth and apoptosis. Human myristoylation is performed by two ubiquitously expressed N-myristoyl-transferases NMT1 and NMT2. PCLX-001 is a new, orally bioavailable, small-molecule, dual NMT inhibitor that is under investigation as a novel and selective treatment for B-cell malignancies. In vitro, PCLX-001 inhibits NMT1 and NMT2 at IC50 of 5nM and 8nM, respectively, inhibits the growth of hematological cancer cells at concentrations 10-fold lower than dasatinib and ibrutinib, and inhibits SFK recruitment to B cell receptor signaling, reducing survival signals and triggering apoptosis. PCLX-001 causes complete tumor regression in NOD/SCID mouse xenograft models of Acute Myeloid Leukemia (AML), Burkitts Lymphoma (BL), and Diffuse Large B-cell Lymphoma (DLBCL), including drug-resistant human tumor in a PDX model. When screened in vitro for its ability to inhibit the activity of 468 kinases and kinase mutants in a KINOMEscan®, PCLX-001 did not inhibit any kinase at up to 10 µM (5380 ng/mL) and produced modest inhibition of only three kinases (MRCKA, PIP5K2B, and SRPK1) at 100 µM (53800 ng/mL). Male rats tolerated single oral doses of PCLX-001 at 100 mg/kg without clear effects, but one of three rats died after a single dose at 1000 mg/kg. Dogs tolerated single oral doses of PCLX-001 at 10 mg/kg without effects, but both dogs showed emesis and diarrhea and lost weight after a single dose at 50 mg/kg. In 21-day xenograft efficacy studies in mice, the maximum tolerated dose level (MTD) was 50mg/kg, which also produced complete tumor remission of most xenografts. Administered daily, the 14-day MTD is >75mg/kg (highest dose tested) in rats and between 5 and 25mg/kg in dogs. The dose-limiting toxicities in dogs involved the gastrointestinal tract and hematopoietic bone marrow. When administered orally, PCLX-001 is 26% bioavailable in rats and >90% bioavailable in mice and dogs. The plasma half-life was 5.7h in mice, 1-2h in rats, and 3.9h in dogs. With repeated daily administration, systemic exposure did not change in dogs but decreased in rats. Based on KINOMEscan® results, PCLX-001 is very unlikely to produce adverse effects in patients due to off-target kinase inhibition. The oral bioavailability and half-life in mice and dogs are consistent with a once-a-day dosing regimen. Repeat dosing studies of up to 21 days in mice and 14 days in rats and dogs determined preliminary MTDs. When extrapolated to human doses based on a body surface area scaling, these MTDs are equivalent to 150mg/m2 in mice, >450mg/m2 in rats, and between 100 and 500 mg/m2 in dogs. These results are consistent with a therapeutic window with potential for tumor response in humans, and support proceeding with 28-day GLP toxicology studies and an IND filing for first in human testing of oral PCLX-001. Disclosures Weickert: Pacylex Pharmaceuticals, Inc.,: Employment. Mackey:Pacylex Pharmaceuticals Inc.: Equity Ownership, Patents & Royalties; illumiSonics Inc: Equity Ownership, Other: Director Role; Pfizer Canada: Honoraria; CME: Honoraria; SMHeartCard Inc: Equity Ownership, Other: Director Role. Berthiaume:Pacylex Pharmaceuticals, Inc.,: Equity Ownership, Patents & Royalties.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
123发布了新的文献求助10
刚刚
无情碧灵发布了新的文献求助10
刚刚
glycine发布了新的文献求助10
1秒前
万能图书馆的应助被李文亚采纳,获得10
1秒前
1秒前
ZDX12135发布了新的文献求助10
2秒前
科研通AI6.4的应助被1101592875采纳,获得10
2秒前
2秒前
3秒前
不爱笑的松鼠完成签到,获得积分10
3秒前
今儿个吃什么完成签到,获得积分10
3秒前
wwwwwww发布了新的文献求助10
3秒前
Qwertyuiop发布了新的文献求助10
4秒前
qqq发布了新的文献求助10
4秒前
zzz完成签到,获得积分10
4秒前
透明的世界的应助被Wb采纳,获得10
4秒前
5秒前
陈帅完成签到,获得积分10
5秒前
林林完成签到 ,获得积分10
5秒前
Miss朱完成签到,获得积分10
5秒前
浅池星完成签到 ,获得积分10
5秒前
苏某人完成签到,获得积分10
5秒前
04d的应助被空白采纳,获得20
6秒前
手可摘棉花糖完成签到,获得积分10
6秒前
Fantasy完成签到,获得积分10
6秒前
Jasper的应助被小荷才露尖尖角采纳,获得30
7秒前
辛勤的梦竹完成签到,获得积分10
7秒前
8秒前
lbj发布了新的文献求助10
8秒前
OI0I完成签到 ,获得积分10
8秒前
8秒前
邓少军发布了新的文献求助20
9秒前
璃月品茶钟离完成签到,获得积分10
9秒前
无情碧灵完成签到,获得积分10
9秒前
可靠松思完成签到,获得积分10
10秒前
10秒前
10秒前
舒心莫言完成签到,获得积分10
10秒前
罗亚亚完成签到,获得积分10
11秒前
方圆几里完成签到,获得积分10
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180757
求助须知:如何正确求助?哪些是违规求助? 9570857
关于积分的说明 21814590
捐赠科研通 7777053
什么是DOI,文献DOI怎么找? 3433314
关于科研通互助平台的介绍 2557579
邀请新用户注册赠送积分活动 2479315